BRKR
HealthcareBruker Corporation · Medical - Devices · $7B
What is Bruker Corporation?
Bruker Corporation develops and manufactures scientific instruments and analytical solutions used in life science research, diagnostics, and industrial applications worldwide.
Bruker generates revenue by selling high-precision instruments and related consumables across three segments: life science tools, nanoscale analysis equipment, and energy and superconducting technologies. Customers include academic researchers, pharmaceutical companies, and industrial labs that rely on Bruker's platforms for molecular analysis, pathogen identification, and materials characterization.
Incorporated in 2000 and headquartered in Billerica, Massachusetts, Bruker serves customers across research, clinical, and industrial markets globally.
- Life science mass spectrometry and MALDI Biotyper pathogen identification
- Atomic force microscopy and X-ray analytical instruments
- Molecular diagnostics kits and PCR-based testing solutions
- Superconducting materials and energy technologies
Is BRKR a Good Stock to Buy?
UQS Score rates BRKR as Below Average overall.
Bruker's Moat and Valuation pillars land at Neutral, reflecting a degree of product specialization in scientific instruments and a valuation that is not dramatically stretched relative to fundamentals.
The Quality, Growth, and Risk pillars all register as Weak, pointing to meaningful headwinds in profitability consistency, revenue momentum, and financial risk management.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BRKR pay dividends?
Yes — Bruker Corporation pays a dividend.
Bruker pays a regular dividend, which is relatively uncommon among mid-cap instrument makers reinvesting heavily in R&D. The dividend signals a degree of capital return discipline, though investors should weigh it alongside the company's Weak Quality and Risk pillar ratings.
When does BRKR report earnings?
Bruker Corporation reports earnings on a quarterly cadence, typical for US-listed equities.
Bruker's recent results have reflected the broader softness in life science instrument demand, with growth and profitability metrics coming under pressure. The Weak Growth pillar rating suggests revenue expansion has lagged expectations across reporting periods.
For the most recent quarter's results, visit Bruker Corporation's investor relations page directly.
BRKR Price History
-41.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
Frequently Asked Questions
What does Bruker Corporation do?
Bruker develops and sells scientific instruments for life science research, nanoscale analysis, diagnostics, and industrial applications. Its platforms are used by researchers, hospitals, and industrial labs to analyze materials and identify pathogens at the molecular level.
Does BRKR pay dividends?
Yes, Bruker pays a regular dividend. For current yield and payment schedule details, check Bruker's investor relations page or your brokerage, as specific figures are not published here.
When does BRKR report earnings?
Bruker reports on a standard quarterly schedule. Exact upcoming dates are best confirmed on Bruker's investor relations page, as our platform does not publish forward earnings dates.
Is BRKR a good stock to buy?
UQS Score rates BRKR as Below Average. Multiple pillars — Quality, Growth, and Risk — are rated Weak, which warrants careful consideration. The full pillar breakdown is available to Pro members for a deeper view.
Is BRKR overvalued?
BRKR's Valuation pillar is rated Neutral, suggesting the stock is neither clearly cheap nor obviously expensive relative to its fundamentals. Given the Weak Quality and Growth ratings, investors may want to weigh what they are paying for.
What is BRKR's market cap bracket?
Bruker Corporation is classified as a mid-cap company, placing it in a tier that typically carries more volatility than large-caps but more stability than small-cap peers in the healthcare instruments space.
Is BRKR a long-term quality indicator?
As a long-term quality indicator, BRKR's current UQS profile is Below Average. Weak scores across Quality, Growth, and Risk pillars suggest the business faces real challenges that long-term investors should monitor closely before committing capital.
What sector does BRKR belong to?
Bruker operates in the Healthcare sector, specifically within scientific and analytical instruments. It serves life science researchers, clinical diagnostics labs, and industrial customers, making it sensitive to research funding cycles and pharma capital spending.
Unlock Full BRKR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete pillar-by-pillar score breakdown for BRKR
- ✓Access full financial metrics and trend data
- ✓Compare BRKR against sector peers on every UQS dimension
- ✓Get the complete analyst view available to Pro members
Pro Analysis
BRKR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 32.6 | 15.3 | 44.0 | 34.7 | 31.2 | 40.9 | 0.0 |
| May 22, 2026 | 32.6 | 15.3 | 44.0 | 34.7 | 31.2 | 41.1 | -0.1 |
| May 21, 2026 | 32.7 | 15.3 | 44.0 | 34.7 | 31.2 | 41.4 | 0.0 |
| May 19, 2026 | 32.7 | 15.3 | 44.0 | 34.7 | 31.2 | 42.0 | 0.0 |
| May 16, 2026 | 32.7 | 15.3 | 44.0 | 34.7 | 31.2 | 41.9 | 0.0 |
| May 15, 2026 | 32.7 | 15.3 | 44.0 | 34.7 | 31.2 | 41.4 | 0.0 |
| May 14, 2026 | 32.7 | 15.3 | 44.0 | 34.7 | 31.2 | 41.5 | +0.1 |
| May 13, 2026 | 32.6 | 15.3 | 44.0 | 34.7 | 31.2 | 41.2 | -0.1 |
| May 12, 2026 | 32.7 | 15.3 | 44.0 | 34.6 | 31.2 | 41.7 | +0.1 |
| May 11, 2026 | 32.6 | 15.3 | 44.0 | 34.6 | 31.2 | 41.4 | +0.3 |
BRKR — Pillar Breakdown
Quality
— 15.3/100 (25%)Bruker Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 34.7/100 (20%)Bruker Corporation faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 31.2/100 (15%)Bruker Corporation presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 40.9/100 (15%)Bruker Corporation has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 44/100 (25%)Bruker Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BRKR.
Score Composition
Financial Data
More Stock Analysis
How is the BRKR UQS Score Calculated?
The UQS (Unified Quality Score) for Bruker Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Bruker Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Bruker Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.